
Internal Reference Number: FOI_9148
Date Request Received: 12/01/2026 00:00:00
Date Request Replied To: 16/01/2026 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Researcher
| Question Number 1: I am analysing the usage of intra-vitreal injections or implants by the NHS. I would greatly appreciate if you could answer the following questions: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2025: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - Lucentis • Ranibizumab - Biosimilar | |
| Answer To Question 1: Please see our response to all questions in the Excel spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below: | |
| Question Number 2: Please provide the number of injections/implants administered within the four-month period from September to December 2025 with the below treatments for noninfectious Uveitis (NIU) only • Dexamethasone • Fluocinolone acetonide | |
| Answer To Question 2: See attached | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.